Fiche publication
Date publication
janvier 2023
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ALPY Fabien
,
Pr CHENARD Marie-Pierre
,
Pr MATHELIN Carole
,
Dr TOMASETTO Catherine
Tous les auteurs :
Lodi M, Voilquin L, Alpy F, Molière S, Reix N, Mathelin C, Chenard MP, Tomasetto CL
Lien Pubmed
Résumé
Pathological complete response (pCR) after neoadjuvant systemic treatment (NST) is an important prognostic factor in HER2-positive breast cancer. The majority of HER2-positive breast cancers are amplified at the HER2 gene locus, several genes are co-amplified with HER2, and a subset of them are co-expressed. The STARD3 gene belongs to the HER2 amplicon, and its role as a predictive marker was never addressed. The objective of this study was to investigate the predictive value of STARD3 protein expression on NST pathological response in HER2-positive breast cancer. In addition, we studied the prognostic value of this marker.
Mots clés
STARD3, breast cancer, human epidermal growth-factor receptor 2 (HER2), neo-adjuvant systemic treatment, pathological complete response
Référence
Cancers (Basel). 2023 01 5;15(2):
